PremaPPeethambaramMDAssociate Professor

PubMed

• Participant Evaluation of a Multi-disciplinary Oncology Preceptorship Training Program for Oncology Health Professionals from Kumasi, Ghana.
  Kenneth W Merrell, Thomas Okpoti Konney, Osei Acheamfour, Joseph Lucido, Abena Yeboah Aduse-Poku, Amanika Kumar, Mavis Bobie Ansah, Adu Tutu Amankwa, Dean Shumway, Fre...> ;Journal of Cancer Education. 2024 Mar 20
• 8 citations
  Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial.
  Tufia C Haddad, Vera J Suman, Antonino B D'Assoro, Jodi M Carter, Karthik V Giridhar, Brendan P McMenomy, Katelyn Santo, Erica L Mayer, Meghan S Karuturi, Aki Morikawa...> ;JAMA Oncology. 2023 Jun 1
• 3 citations
  Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study.
  Grace M Choong, Savannah Liddell, Roberto A Leon Ferre, Ciara C O'Sullivan, Kathryn J Ruddy, Tufia C Haddad, Timothy J Hobday, Prema P Peethambaram, Minetta C Liu, Mat...> ;Breast Cancer Research and Treatment. 2022 Nov 1
• 1 citations
  Changes in Frequency of Surveillance Imaging of Survivors of Diffuse Large B-Cell Lymphoma After the American Society of Hematology Choosing Wisely Recommendations.
  Urshila Durani, Dennis Asante, Herbert C. Heien, Carrie A. Thompson, Thorvardur R. Halfdanarson, Lindsey R. Sangaralingham, Prema P. Peethambaram, Fernando Quevedo, Jo...> ;JCO Oncology Practice. 2020 Oct 23
• 48 citations
  Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer
  Siddhartha Yadav, Chunling Hu, Steven N. Hart, Nicholas J. Boddicker, Eric C. Polley, Jie Na, Rohan Gnanaolivu, Kun Y. Lee, Tricia Lindstrom, Sebastian M. Armasu, Patr...> ;Journal of Clinical Oncology. 2020 Mar 3
• 1 citations
  Use of Imaging During Staging and Surveillance of Localized Colon Cancer in a Large Insured Population.
  Urshila Durani, Dennis Asante, Thorvardur R. Halfdanarson, Herbert C. Heien, Lindsey R. Sangaralingham, Carrie A. Thompson, Prema P. Peethambaram, Fernando Quevedo, Ro...> ;Journal of the National Comprehensive Cancer Network. 2019 Nov 1
• 21 citations
  Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer.
  Tufia C. Haddad, Antonino B. D'Assoro, Vera J. Suman, Mateusz Opyrchal, Prema P. Peethambaram, Minetta C. Liu, Matthew P. Goetz, James N. Ingle> ;Breast Cancer Research and Treatment. 2018 Apr 1
• 14 citations
  Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2- node positive breast cancer-A National Cancer Database study.
  Prema P. Peethambaram, Tanya L. Hoskin, Courtney N. Day, Matthew P. Goetz, Elizabeth B. Habermann, Judy C. Boughey> ;NPJ Breast Cancer. 2017 Oct 19
• A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors.
  Peethambaram, P. P.,Hartmann, L. C.,Jonker, D. J.,de Jonge, M.,Plummer, E. R.,Martin, L.,Konner, J.,Marshall, J.,Goss, G. D.,Teslenko, V.,Clemens, P. L.,Cohen, L. J.,A...> ;Invest New Drugs. 2014 Nov 09
• 60 citations
  Risk-scoring models for individualized prediction of overall survival in low-grade and high-grade endometrial cancer.
  Mariam M. AlHilli, Andrea Mariani, Jamie N. Bakkum-Gamez, Sean C. Dowdy, Amy L. Weaver, Preema P. Peethambaram, Gary L. Keeney, William A. Cliby, Karl C. Podratz> ;Gynecologic Oncology. 2014 Jun 1
• 7 citations
  Safety of pegfilgrastim (neulasta) in patients with sickle cell trait/anemia.
  Pashtoon Murtaza Kasi, Mrinal M. Patnaik, Prema P. Peethambaram> ;Case Reports in Hematology. 2013 Dec 11
• 4 citations
  Self-perceptions of age among 292 chemotherapy-treated cancer patients: Exploring associations with symptoms and survival
  Ming Y. Lim, Elisabeth K. Stephens, Paul J. Novotny, Katharine A. Price, Marcia Salayi, Lindsey E. Roeker, Prema P. Peethambaram, Aminah Jatoi> ;Journal of Geriatric Oncology. 2013 Jul 1
• 1 citations
  Soyfood consumption in breast cancer survivors: don't overstate the facts!
  Prema P. Peethambaram, Janet E. Olson, Charles L. Loprinzi> ;Oncology. 2013 May 15
• 39 citations
  A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261
  Keith C. Bible, Prema P. Peethambaram, Ann L. Oberg, William J. Maples, David L. Groteluschen, Matthew P. Boente, Jill K. Burton, Leigh C. Gomez Dahl, Jennifer D. Tibo...> ;Gynecologic Oncology. 2012 Oct 1
• 18 citations
  A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma
  Andrea E. Wahner Hendrickson, Ann L. Oberg, Gretchen E. Glaser, John K. Camoriano, Prema P. Peethambaram, Gerardo Colon-Otero, Charles Erlichman, S. Percy Ivy, Scott H...> ;Gynecologic Oncology. 2012 Feb 1
• 6 citations
  Cutaneous presentation of a distant metastasis of malignant phyllodes tumor.
  Ryan E. Swapp, Wonwoo Shon, Prema P. Peethambaram, Steven L. Moran, Carol Reynolds> ;International Journal of Dermatology. 2012 Jan 1
• 1 citations
  Consumer beware: a systematic assessment of potential bias in the lay electronic media to examine the portrayal of "PARP" inhibitors for cancer treatment.
  Shawnta Coleman, Prema P. Peethambaram, Aminah Jatoi> ;Journal of Cancer Education. 2011 Sep 1
• 32 citations
  Assessment of Hepatocyte Growth Factor in Ovarian Cancer Mortality
  Ellen L. Goode, Georgia Chenevix-Trench, Lynn C. Hartmann, Brooke L. Fridley, Kimberly R. Kalli, Robert A. Vierkant, Melissa C. Larson, Kristin L. White, Gary L. Keene...> ;Cancer Epidemiology, Biomarkers & Prevention. 2011 Aug 1
• 48 citations
  Phase II Trial of Lapatinib and Topotecan (LapTop) in Patients with Platinum-Refractory/Resistant Ovarian and Primary Peritoneal Carcinoma
  S. John Weroha, Ann L. Oberg, Katie L. Allen Ziegler, Shaker R. Dakhilm, Kendrith M. Rowland, L. C. Hartmann, Dennis F. Moore, Gary L. Keeney, Prema P. Peethambaram, P...> ;Gynecologic Oncology. 2011 Jul 1
• 4 citations
  Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or pr...
  Mark R. Litzow, Prema P. Peethambaram, Stephanie L. Safgren, Gary L. Keeney, S. M. Ansell, Angela Dispenzieri, Michelle A. Elliott, Dennis A. Gastineau, Morie A. Gertz...> ;Bone Marrow Transplantation. 2010 Mar 1
• 55 citations
  Inherited determinants of ovarian cancer survival.
  Ellen L. Goode, Matthew J. Maurer, Thomas A. Sellers, Catherine M. Phelan, Kimberly R. Kalli, Brooke L. Fridley, Robert A. Vierkant, Sebastian M. Armasu, Kristin L. Wh...> ;Clinical Cancer Research. 2010 Feb 1
• 219 citations
  Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
  Evanthia Galanis, Lynn C. Hartmann, William A. Cliby, Harry J. Long, Prema P. Peethambaram, Brigitte A. Barrette, Judith S. Kaur, Paul Haluska, Ileana Aderca, Paula J....> ;Cancer Research. 2010 Feb 1
• 54 citations
  A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu.
  Prema P. Peethambaram, Michelle E. Melisko, Kristine Rinn, Steven R. Alberts, Nicole M. Provost, Lori A. Jones, Robert B. Sims, Lisa R. C. Lin, Mark W. Frohlich, John ...> ;Clinical Cancer Research. 2009 Sep 15
• 11 citations
  Centering Prayer for Women Receiving Chemotherapy for Recurrent Ovarian Cancer: A Pilot Study
  Mary E. Johnson, Ann Marie Dose, Teri Britt Pipe, Wesley O. Petersen, Mashele Huschka, Mary M. Gallenberg, Prema P. Peethambaram, Jeff A. Sloan, Marlene H. Frost> ;Oncology Nursing Forum. 2009 Jul 6
• Phase I trial of Intraperitoneal (IP) administration of a measles virus (MV) derivative expressing the human carcinoembryonic antigen (CEA) in recurrent ovarian cancer...
  Galanis E, Hartmann LC, Cliby W, Peethambaram PP, Long HJ, Kaur JS, Haluska P, Sloan JA, Peng K, Russell SJ> ;J. Clin. Oncol.. 2008-05-20
• Join now to see all

Journal Articles

• Soyfood consumption in breast cancer survivors: Don't overstate the facts!  
  Peethambaram P, Olson J, Loprinzi CL, Oncology, 1/1/2013
• Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival  
  Sarris AH, Kliche KO, Pethambaram P, Preti A, Tucker S, Jackow C, Messina O, Pugh W, Hagemeister FB, McLaughlin P, Rodriguez MA, Romaguera J, Fritsche H, Witzig T, Duv..., Ann Oncol, 4/1/1999
• Toxicity of systemic adjuvant chemotherapy for colorectal cancer  
  Peethambaram PP, O'Connell MJ, Seminars in Colon & Rectal Surgery, 1/1/1996
• Long-term functional results and complications after combined modality adjuvant therapy for rectal carcinoma  
  Kollmorgen CF, Peethambaram PP, Wolff BG, Seminars in Colon & Rectal Surgery, 1/1/1996
• Join now to see all

Books/Book Chapters

• Supportive Care in Cancer: A Handbook for Oncologists 
  Chapter: Management of cancer anorexia and cachexia. 
  Page 297 - 308Peethambaram PP, Loprinzi CLEditors: Klastersky J, et al.Marcel Dekker, Inc., New York, NYEdition 2nd,1999
• Principles and Practice of Supportive Oncology 
  Chapter: Cancer anorexia/cachexia. 
  Page 133 - 139Loprinzi CL, Goldberg RM, Peethambaram PPEditors: Berger A, et al.Lippincott-Raven Publishers, Philadelphia1998

Abstracts/Posters

• Phase i dose-escalation and drug interaction study of abt-888 (parp1 inhibitor) and topotecan (topoisomerase I inhibitor) in patients with advanced cancer.
  Boakye-Agyeman F, Reid J, Menefee M, Buhrow S, Walden C, Piens J, Kayode O, Erlichman C, Haluska P, Northfelt DW, Kaufmann SH, Ames M, Satele DV, Tang H, Peethambaram ..., Clin Pharmacol Ther, 3/1/2014
• Results from two phase 1 trials of HER2/NEU-directed active cellular immunotherapy in patients with advanced malignancies.
  Sims RB, Park JW, Peethambaram PP, Melisko M, Rinn KJ, Alberts SR, Provost NM, Ann Oncol, 10/1/2010
• Phase II trial of lapatinib in combination with weekly topotecan in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.
  Haluska P, Oberg AL, Dakhil SR, Ziegler KLA, Rowland KM, Hartmann LC, Moore DF, Keeney GL, Peethambaram PP, Ann Oncol, 5/1/2009
• A phase 2 trial of flavopiridol and cisplatin in platinum-resistant ovarian cancer.
  Peethambaram PP, Burton JK, Oberg AL, Gomez-Dahl LC, Isham CR, Tibodeau JD, Chomjak TL, Colevas AD, Wright JJ, Erlichman C, Bible KC, Molecular Cancer Therapeutics, 12/1/2007
• Phase I trial of intraperitoneal (IP) administration of a measles virus (MV) derivative expressing the human carcinoembryonic antigen (CEA) in ovarian cancer patients.
  Galanis E, Hartmann LC, Cliby W, Zollman PJ, Peethambaram PP, Long HJ, Kaur JS, Sloan JA, Peng KW, Russell SJ, J Clin Oncol, 6/1/2006
• An open-label study of autologous dendritic cells loaded with escalating doses of Her500hGM (APC8024) in patients with treatment refractory metastatic tumors that over...
  Prema P. Peethambaram, MD, ASCO, New Orleans, LA, 6/1/2004
• Immunotherapy targeting HER2/Neu: results from Phase I studies of APC8024 in women with metastatic breast cancer.
  Melisko ME, Peethambaram P, Rinn K, Jones LA, Sims RB, Park JW, Breast Cancer Res Treat, 1/1/2004
• A phase I trial of the farnesyltransferase (FT) inhibitor, BMS-214662 (B) in combination with paclitaxel (P) and carboplatin (C) in patients with advanced cancer.
  Dy GK, Bruzek LM, Croghan GA, Mandrekar S, Peethambaram P, Hanson LJ, Erlichman C, Cheng S, Proc Am Soc Clin Oncol, 1/1/2004
• A phase I trial of topotecan combined with cyclophosphamide and carboplatin with autologous blood stem cell transplant for the treatment of relapsed or persistent ovar...
  Peethambaram P, Litzow M, Safgren S, Hartmann L, Barrette B, Long H, Suman V, Reid J, Ames M, Kaufmann S, Proceedings of ASCO, 1/1/2003
• A phase I study of sequential gemcitabine and MTA (LY231514) in patients with advanced malignancies.
  Adjei A, Erlichman C, Pitot H, Sloan J, Goldberg R, Peethambaram P, Hanson L, Reid J, Johnson R, Eur J Cancer, 9/1/1999
• sCD30, progression-free survival (PFS), and survival (SURV) in hodgkins disease (HD) patients (PTS).
  Nadali G, Sarris H, Viviani S, Bonfante V, Micheletti M, Notti P, Peethambaram P, Preti A, Hagemeister F, Romaguera J, McLaughlin P, Rodriguez A, Tsimberidou M, Chilos..., Blood, 1/1/1999
• Serum IL-10, EBV latency and cure of Hodgkins disease.
  Sarris AH, Viviani S, Bonfante V, Kliche KO, Herling M, Khorana S, Notti P, Medeiros LJ, Peethambaram P, Hagemeister F, Cox R, Tucker S, Preti A, Witzig T, Bonadonna G..., Genes and Immunity, 1/1/1999
• Serum IL-10 and progression-free survival (PFS) in hodgkins disease (HD) patients (PTS) treated only with radiotherapy (RT).
  Sarris AH, Viviani S, Bonfante V, Nadali G, Kliche KO, Micheletti M, Notti P, Peethambaram P, Preti A, Hagemeister F, Romaguera J, McLaughlin P, Rodriguez A, Chilosi M..., Blood, 1/1/1999
• A Phase I trial of MTA (multi-targeted antifolate, LY231514) and gemcitabine (Gemzar) in patients with locally advanced or metastatic cancer.
  Erlichman C, Adjei A, Sloan J, Pitot H, Goldberg R, Peethambaram P, Alberts S, Galanis E, Hanson L, Reid J, Rubin J, Burch P, Thornton D, Walling J, Program/Proc Am Soc Clin Oncol, 1/1/1999
• Serum IL-10 and cure of Hodgkins disease.
  Kliche KO, Viviani S, Notti P, Medeiros LJ, Peethambaram P, Tucker S, Preti A, Witzig T, Bonadonna F, Sarris AH, Onkologie; Annual Meeting of the German and Austrian Society for Hematology and Oncology, Jena, Germany, October 3-6, 1999, 1/1/1999
• Serum interleukin 10(IL-10) and failure free survival (FFS) of adult Hodgkin's disease (HD).
  Prema P. Peethambaram, MD, The Fourth International Symposium on Hodgkin's Lymphoma, Koln, Germany, 3/1/1998
• A prognostic model for Hodgkin's Disease based on IL 10.
  Prema P. Peethambaram, MD, American Society of Hematology, 1/1/1998
• Phase II trial of primary chemotherapy followed by reduced dose radiation for CNS germ cell tumors.
  Buckner JC, Peethambaram PP, Smithson WA, et al, J Neuro-Oncol, 1/1/1998
• Primary chemotherapy followed by reduced dose radiation for central nervous system germ cell tumors.
  Buckner JC, Peethambaram PP, Smithson WA, Groover RV, Schomberg PJ, Kimmel DW, Raffel C, O'Fallon JR, Shaw EG, J Neuro-Oncology, 1/1/1998
• Cancer, anorexia, and cachexia.
  Peethambaram PP, Central Line, 1/1/1998
• A prognostic model for Hodgkin's Disease based on IL 10.
  Sarris AH, Viviani S, Bonfante V, Kliche KO, Notti P, Peethambaram PP, et al, Blood, 1/1/1998
• Serum interleukin-10 (IL-10) and failure-free survival (ff) of adult Hodgkin's disease (HD).
  Harris AH, Kliche KO, Peethambaram P, Preti A, Jackow C, Mesina O, Hagemeister F, McLaughlin P, Rodriguez MA, Romaguera J, Fritsche H, Duvic M, Witzig T, Andreeff M, C..., Leuk Lymphoma, 1/1/1998
• Interleukin-10 as a prognostic factor for Hodgkin's disease treated with ABVD: results from MD Anderson and Mayo Clinic.
  Sarris AH, Klilche KO, Peethambaram PP, Witzig TE, Andreeff M, Cabanillas F, Blood, 11/1/1997
• Interleukin-10 as a prognostic factor for Hodgkin's disease (HD) treated with ABVD: Results from MD Anderson and Mayo Clinic.
  Prema P. Peethambaram, MD, American Society of Hematology, 1/1/1997
• Acquired Glanzmann's thrombasthenia (GT) in a patient with chronic large granular lymphocytic leukemia (CLGLL).
  Peethambaram PP, Okuno SH, Daniels TM, Litzow MR, Nichols WL, Blood, 11/15/1995
• Join now to see all

Lectures

• Androgens and anti-androgens to treat breast cancer. 
  Rochester, MN - 3/1/2013
• The "pain" truth about aromatase inhibitors. 
  Rochester, MN - 5/1/2012
• "Journal club" 
  Rochester, MN - 8/1/2011
• Oncotype DX in node positive breast cancer. 
  Rochester, MN - 4/1/2009
• Medical management of gynecologic cancers. 
  Rochester, MN - 10/1/2008
• Chemotherapy, gemcitabine, and etoposide. 
  Rochester, MN - 4/1/2008
• Phase II trial of Flavopiridol combined with cisplatin in ovarian cancer. 
  Rochester, MN - 9/1/2007
• EGFR positive breast cancer. 
  Rochester, MN - 5/1/2007
• Responding to allergic reactions with taxol chemotherapy. 
  Rochester, MN - 1/1/2005
• ASCO updates on gynecologic cancers. 
  Rochester, MN - 8/1/2004
• Chemotherapy for ovarian cancer. 
  Rochester, MN - 11/1/2001
• Ovarian cancer. 
  Albert Lea, MN - 1/1/2000
• Update in treatment of ovarian cancer for internists. 
  Austin, MN - 1/1/1999
• "Primary chemotherapy followed by reduced dose radiation for central nervous system germ cell tumors" 
  3/1/1998
• Inherited breast and ovarian cancer. 
  Black Hills, SD - 1/1/1998
• Recent advances in systemic therapy for ovarian cancer. 
  Rochester, MN
• Join now to see all